Transplant outcomes by donor type
| Outcome . | Donor type . | P . | |
|---|---|---|---|
| Haplo, % (95% CI) . | MUD, % (95% CI) . | ||
| Reduced-intensity regimen | |||
| Day-28 neutrophil recovery | 90 (88-92) | 96 (93-98) | <.001 |
| Day-100 platelet recovery | 88 (86-90) | 95 (92-98) | <.001 |
| 2-y graft failure | 11 (8-13) | 3 (1-7) | <.001 |
| Day-100 grades 2 to 4 acute GVHD | 29 (27-32) | 29 (22-36) | .17 |
| Day-100 grades 3 and 4 acute GVHD | 9 (7-10) | 4 (2-8) | .02 |
| 2-y chronic GVHD | 27 (25-30) | 29 (22-36) | .70 |
| 2-y relapse | 42 (39-45) | 37 (30-45) | .22 |
| 2-y nonrelapse mortality | 16 (14-19) | 8 (5-13) | <.001 |
| 2-y disease-free survival | 41 (38-45) | 55 (47-62) | .002 |
| 2-y overall survival | 54 (51-57) | 67 (60-74) | .001 |
| Myeloablative regimen | |||
| Day-28 neutrophil recovery | 94 (92-95) | 96 (91-99) | .31 |
| Day-100 platelet recovery | 87 (85-89) | 93 (87-97) | <.0001 |
| 1-y graft failure | 4 (3-6) | 3 (1-8) | .60 |
| Day-100 grades 2 to 4 acute GVHD | 33 (30-37) | 32 (23-41) | .73 |
| Day-100 grades 3 and 4 acute GVHD | 10 (8-12) | 4 (1-9) | .02 |
| 1-y chronic GVHD | 33 (30-36) | 25 (17-34) | .09 |
| 1-y relapse | 19 (17-22) | 21 (23-41) | .74 |
| 1-y nonrelapse mortality | 15 (13-18) | 15 (8-23) | .97 |
| 1-y disease-free survival | 66 (62-69) | 65 (54-74) | .81 |
| 1-y overall survival | 75 (72-78) | 77 (68-85) | .59 |
| Outcome . | Donor type . | P . | |
|---|---|---|---|
| Haplo, % (95% CI) . | MUD, % (95% CI) . | ||
| Reduced-intensity regimen | |||
| Day-28 neutrophil recovery | 90 (88-92) | 96 (93-98) | <.001 |
| Day-100 platelet recovery | 88 (86-90) | 95 (92-98) | <.001 |
| 2-y graft failure | 11 (8-13) | 3 (1-7) | <.001 |
| Day-100 grades 2 to 4 acute GVHD | 29 (27-32) | 29 (22-36) | .17 |
| Day-100 grades 3 and 4 acute GVHD | 9 (7-10) | 4 (2-8) | .02 |
| 2-y chronic GVHD | 27 (25-30) | 29 (22-36) | .70 |
| 2-y relapse | 42 (39-45) | 37 (30-45) | .22 |
| 2-y nonrelapse mortality | 16 (14-19) | 8 (5-13) | <.001 |
| 2-y disease-free survival | 41 (38-45) | 55 (47-62) | .002 |
| 2-y overall survival | 54 (51-57) | 67 (60-74) | .001 |
| Myeloablative regimen | |||
| Day-28 neutrophil recovery | 94 (92-95) | 96 (91-99) | .31 |
| Day-100 platelet recovery | 87 (85-89) | 93 (87-97) | <.0001 |
| 1-y graft failure | 4 (3-6) | 3 (1-8) | .60 |
| Day-100 grades 2 to 4 acute GVHD | 33 (30-37) | 32 (23-41) | .73 |
| Day-100 grades 3 and 4 acute GVHD | 10 (8-12) | 4 (1-9) | .02 |
| 1-y chronic GVHD | 33 (30-36) | 25 (17-34) | .09 |
| 1-y relapse | 19 (17-22) | 21 (23-41) | .74 |
| 1-y nonrelapse mortality | 15 (13-18) | 15 (8-23) | .97 |
| 1-y disease-free survival | 66 (62-69) | 65 (54-74) | .81 |
| 1-y overall survival | 75 (72-78) | 77 (68-85) | .59 |